News
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...
The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...
The third death occurred in an adult male with limb girdle muscular dystrophy who received a Sarepta AAVrh74 gene therapy product, SRP-9004, in a phase 4 clinical trial.
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, ...
The Food & Drug Administration is investigating the death of an 8‑year‑old following Elevidys gene therapy for Duchenne ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
1h
Stocktwits on MSNRetail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy
Retail sentiment around Sarepta Therapeutics remained upbeat on Monday after the company said Friday that the death of an ...
US regulators are investigating the death of an 8-year-old boy in Brazil who received Sarepta Therapeutics Inc.’s Elevidys.
NEW YORK, NY / ACCESS Newswire / June 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT) concerning possible ...
NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT) concerning ...
NEW YORK, NY / ACCESS Newswire / June 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT) concerning ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results